

**Bio393: Genetic Analysis****Name:** \_\_\_\_\_**Problem Set #7****Due on Friday, March 9, 3 PM****Question 1:**

Imagine you are doing a genome-wide linkage study in Finnish families looking for the genetic determinants of blood pressure in humans. You have five multi-generational families; each individual is genotyped at 1000 markers and his/her blood pressure is measured. A recent, published study in Icelandic families identified a highly significant locus on chromosome 10 responsible for blood pressure variation. You look through your results and see no significant linkage between the genotype and the disease in your data. Your nearest marker to this locus is 30 cM away.

Give three reasons why you might have failed to find linkage to the chromosome 10 locus. Please explain each reason with no more than one to two sentences.

**Question 2:**

You are studying a rare recessive disease that you have mapped approximately by linkage to simple sequence repeat (SSR) markers. In an effort to localize the disease locus more precisely, you decide to look for linkage disequilibrium (LD) with respect to two dimorphic DNA-based markers (designated A and B) known to be in the vicinity of the disease gene. You first examine a relatively isolated Scandinavian population in which the frequencies of alleles A1 and A2 are 0.9 and 0.1 respectively, and the frequencies of B1 and B2 are both 0.5. By examining the DNA from individuals in the population who have the disease it is possible to determine the frequency of each haplotype, as shown in the table below.

Haplotype	Number of individuals with the disease
A1 B1	10
A1 B2	90
A2 B1	1
A2 B2	10

**(a)** (i) What can you say about possible linkage disequilibrium between each of the markers and the disease causing allele in this population? (ii) Assume the disease causing allele arose after both of the markers (A and B) were present in the population. Which of the two DNA-based markers is likely to be closer to the disease locus? (iii) Assuming that the disease allele arose only once in this population, what can you say about the haplotype context in which the original disease mutation arose?

**(b)** Next you examine the genotypes of individuals with the same disease in a large African population. In this population the frequencies of alleles A1 and A2 are both 0.5, and the frequencies of B1 and B2 are also both 0.5. The frequencies of the each haplotype for individuals with the disease in the African population are shown in the table below.

Haplotype	Number of individuals with the disease
A1 B1	26
A1 B2	24
A2 B1	28
A2 B2	22

Give two different explanations for why the linkage disequilibrium results differ between the African and Scandinavian populations.

**Question 3:**

You are running a case-control GWAS for Type 2 Diabetes. Of the 500,000 variants you test, one variant (rs4514, which has 2 alleles, A and G) near the *sweetums* gene has good separation between cases and controls. You have 1000 cases, (480 of which are AA, 400 are AG, and 120 are GG at rs4514) and 1000 controls, (360 of which are AA, 440 are AG, and 200 are GG at rs4514).


**(a)** Using a chi-squared test, what is the p-value of the association of these alleles with the disease.

**(b)** Given that you did 500,000 tests, what is your (Bonferroni) corrected threshold for p-value significance (initial  $\alpha=0.05$ )? Does the rs4514 variant pass “genome-wide significance” for association with Type 2 Diabetes?

**(c)** What is the odds ratio of this variant in a risk for Type 2 Diabetes?

**Question 4:**

A patient comes into your medical office presenting his 23andme results and an extreme sense of worry. He is completely confused about how 23andme determined that he has a reduced risk for gout, especially because he loves fatty foods. Please briefly explain in words how his risk can be less than 1x and how they calculated it.

NAME	YOUR RISK	AVG. RISK	COMPARED TO AVERAGE
Gout	17.1%	22.8%	0.75x 
Venous Thromboembolism	9.0%	12.3%	0.73x 
Alzheimer's Disease	4.3%	7.2%	0.60x 
Age-related Macular Degeneration	3.1%	6.5%	0.48x 
Melanoma	2.2%	2.9%	0.75x 